Efficacy of artemether-lumefantrine as a treatment for uncomplicated Plasmodium vivax malaria in eastern Sudan

Tajeldin M Abdallah, Abdel Aziem A Ali, Mohammed Bakri, Gasim I Gasim, Imad R Musa, Ishag Adam, Tajeldin M Abdallah, Abdel Aziem A Ali, Mohammed Bakri, Gasim I Gasim, Imad R Musa, Ishag Adam

Abstract

Background: Artemisinin-based combination therapy (ACT) is the treatment of choice for uncomplicated Plasmodium falciparum malaria in most areas of the world, where malaria is endemic, including Sudan. However, few published data are available on the use of ACT for treatment of P. vivax malaria.

Methods: This study was conducted at a health centre in Kassala, eastern Sudan, from October to December 2011. Patients with uncomplicated P. vivax malaria received artemether-lumefantrine (AL) tablets (containing 20mg artemether and 120 mg lumefantrine) and were monitored for 28 days.

Results: Out of the 43 cases enrolled in this study, 38 completed the 28-day follow-up. Their mean age was 25.1 years (SD: 1.5). On day 3 following AL treatment, all of the patients were afebrile and aparasitaemic. By day 28, all 38 patients exhibited adequate clinical and parasitological responses to AL treatment. The cure rate was 100% and 88.4% for the per protocol analysis andfor the intention to treat analysis, respectively. Mild adverse effects (nausea, vomiting, abdominal pain, dizziness and/or rash) that resolved spontaneously were observed in four (10.5%) of the patients.

Conclusion: AL combination therapy was fully effective for treatment of P. vivax malaria in the study in eastern Sudan.

Trial registration: Trial. Gov: NCT01625871.

Figures

Figure 1
Figure 1
Map of Sudan.
Figure 2
Figure 2
Patient enrollment and follow-up during the study.

References

    1. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar IR, Baird JK, Snow RW, Hay SI. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis. 2010;4:e774. doi: 10.1371/journal.pntd.0000774.
    1. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001;64:97–106.
    1. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis. 2009;9:555–566. doi: 10.1016/S1473-3099(09)70177-X.
    1. Yohannes AM, Teklehaimanot A, Bergqvist Y, Ringwald P. Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia. Am J Trop Med Hyg. 2011;84:137–140. doi: 10.4269/ajtmh.2011.09-0723.
    1. Nigatu W, Abebe M, Dejene A. Plasmodium vivax and P. falciparum epidemiology in Gambella, south-west Ethiopia. Trop Med Parasitol. 1992;43:181–185.
    1. Jima D, Getachew A, Bilak H, Steketee RW, Emerson PM, Graves PM, Gebre T, Reithinger R, Hwang J. Ethiopia Malaria Indicator Survey Working Group: Malaria indicator survey 2007 Ethiopia: coverage and use of major malaria prevention and control interventions. Malar J. 2010;9:58. doi: 10.1186/1475-2875-9-58.
    1. Animut A, Mekonnen Y, Shimelis D, Ephraim E. Febrile illnesses of different etiology among outpatients in four health centers in Northwestern Ethiopia. J Infect Dis. 2009;62:107–110.
    1. Mahgoub H, Gasim GI, Musa IR, Adam I. Severe Plasmodium vivax malaria among Sudanese children at New Halfa Hospital Eastern Sudan. Parasit Vectors. 2012;5:154. doi: 10.1186/1756-3305-5-154.
    1. Abdalla SI, Malik EM, Ali KM. The burden of malaria in Sudan: incidence, mortality and disability–adjusted life—years. Malar J. 2007;6:97. doi: 10.1186/1475-2875-6-97.
    1. Adam I, Salah MT, Eltahir HG, Elhassan AH, Elmardi KA, Malik EM. Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan. Ann Trop Med Parasitol. 2010;104:319–326. doi: 10.1179/136485910X12743554760144.
    1. Adam I, Osman ME, Elghazali G, Ahmed GI, Gustafson LL, Elbashir MI. Efficacies of chloroquine, sulphadoxine–pyrimethamine and quinine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan. Ann Trop Med Parasitol. 2004;98:661–666. doi: 10.1179/000349804225021514.
    1. World Health Organization. Implementation of the Global Malaria Control Strategy. Report of a WHO Study Group on the Implementation of the Global Plan of Action for Malaria Control 1993–2000. Technical Report Series no. 839. World Health Organization, Geneva; 1993.
    1. Quique B. The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria. PLoS Negl Trop Dis. 2011;12:e1325.
    1. Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine? Lancet. 1989;2:1183–1184.
    1. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009;22:430–435. doi: 10.1097/QCO.0b013e32832f14c1.
    1. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis. 2010;10:405–416. doi: 10.1016/S1473-3099(10)70079-7.
    1. Malik EM, Mohamed TA, Elmardi KA, Mowien RM, Elhassan AH, Elamin SB, Mannan AA, Ahmed ES. From chloroquine to artemisinin-based combination therapy: the Sudanese experience. Malar J. 2006;5:6. doi: 10.1186/1475-2875-5-6.
    1. Osman MM, Nour BY, Sedig MF, De Bes L, Babikir AM, Mohamedani AA, Mens PF. Informed decision-making before changing to RDT: a comparison of microscopy, rapid diagnostic test and molecular techniques for the diagnosis and identification of malaria parasites in Kassala, eastern Sudan. Trop Med Int Health. 2010;15:1442–1448. doi: 10.1111/j.1365-3156.2010.02659.x.
    1. WHO. Methods for surveillance of antimalarial drug efficacy. 2009. .
    1. Sagara I, Rulisa S, Mbacham W, Adam I, Sissoko K, Maiga H, Traore OB, Dara N, Dicko YT, Dicko A, Djimdé A, Jansen FH, Doumbo OK. Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial. Malar J. 2009;8:63. doi: 10.1186/1475-2875-8-63.
    1. Elamin SB, Malik EM, Abdelgadir T, Khamiss AH, Mohammed MM, Ahmed ES, Adam I. Artesunate plus sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in Sudan. Malar J. 2005;4:41. doi: 10.1186/1475-2875-4-41.
    1. Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I, Muchohi S, Kokwaro G, Aseffa A, Engers H. Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit,Ethiopia. Malar J. 2008;7:220. doi: 10.1186/1475-2875-7-220.
    1. Krudsood S, Tangpukdee N, Muangnoicharoen S, Thanachartwet V, Luplertlop N, Srivilairit S, Wilairatana P, Kano S, Ringwald P, Looareesuwan S. Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Korean J Parasitol. 2007;45:111–114. doi: 10.3347/kjp.2007.45.2.111.
    1. Alvarez G, Piñeros JG, Tobón A, Ríos A, Maestre A, Blair S, Carmona-Fonseca J. Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. Am J Trop Med. 2006;76:605–609.
    1. Naing C, Aung K, Win DK, Wah MJ. Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries. Trans R Soc Trop Med. 2010;104:695–705. doi: 10.1016/j.trstmh.2010.08.009.
    1. Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother. 2004;48:4075–4083. doi: 10.1128/AAC.48.11.4075-4083.2004.
    1. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev. 2009;22:508–534. doi: 10.1128/CMR.00008-09.
    1. Sutanto I, Endawati D, Ling LH, Laihad F, Setiabudy R, Baird JK. Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia. Malar J. 2010;9:52. doi: 10.1186/1475-2875-9-52.
    1. Ketema T, Bacha K, Birhanu T, Petros B. Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. Malar J. 2009;8:177. doi: 10.1186/1475-2875-8-177.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe